1-3 of 3
Michelle Moh
Close
Sort by
Journal Articles

Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML

Clinical Trials & Observations
Joseph M. Scandura, Gail J. Roboz, Michelle Moh, Ewelina Morawa, Fabienne Brenet, J. Robi Bose, Luis Villegas, Usama S. Gergis, Sebastian A. Mayer, Cindy M. Ippoliti, Tania J. Curcio, Ellen K. Ritchie, Eric J. Feldman
Journal: Blood
Blood (2011) 118 (6): 1472–1480.
https://doi.org/10.1182/blood-2010-11-320093
Published: 2011
Includes: Supplemental data
Journal Articles

Genome-Wide Analysis of DNA Methylation Patterns Reveals Dynamic Epigenetic Regulation of the AML Genome After Decitabine Treatment.

Fabienne Brenet, Ph.D., Michelle Moh, MS, Patricia Funk, BS, Daoqui You, MS, Agnes J. Viale, Ph.D., Nicholas D. Socci, PhD, Joseph M. Scandura, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 591.
https://doi.org/10.1182/blood.V114.22.591.591
Published: 2009
Journal Articles

Epigenetic Priming with Decitabine Prior to Standard Induction Chemotherapy in Less-Than-Favorable Risk Acute Myelogenous Leukemia (AML).

Joseph M. Scandura, MD, PhD, Gail J. Roboz, MD, Michelle Moh, MS, Jahar R Bose, Usama S Gergis, MD, Sebastian A Mayer, MD, Cindy Ippoliti, PharmD, Curcio J Tania, RN, Ellen K Ritchie, MD, Eric J. Feldman, MD
Journal: Blood
Blood (2009) 114 (22): 3079.
https://doi.org/10.1182/blood.V114.22.3079.3079
Published: 2009